Notably, it is worthwhile to measure all possible qualitative transcriptional signatures together (“a panel for all”) for disease diagnosis, histological classification, prognosis and drug evaluation of lung cancer through a single whole (or a large panel of genes) RNA-sequencing for a sample to aid or even replace multiple conventional clinical detection, which could preserve precious tissue for the other molecular testing such as EGFR mutation detection. The gene discussed is EGFR; the disease is lung carcinoma.